Table 7.
Renal outcomes and prognostic indicators for patients with biopsy-proven HN in the present study and in previous reports
| Case numbers | Sex (male:female) | Age (y) | Scr (eGFR) | Proteinuria (g/24 h) | BP (mmHg) | Duration of follow-up (y) | Renal outcomes | Predictors of renal survival | |
|---|---|---|---|---|---|---|---|---|---|
| Takebayashi [21] | 590 | 2.5:1 | 56.5 | 1.90(ND) | ND | 154(SBP) 87(DBP) |
10.1 | 49.2 % of 345 cases reached endpoint event (Scr ≥3 mg/dl) | Poor or no control of BP, global glomerulosclerosis (>40 %), presence of collapsed glomeruli and/or segmental glomerulosclerosis |
| Marcantoni [22] | 62a | 1.3:1 | 58.7 | 3.40(ND) | 1.8 | 105 ± 3(MAP) | 1.9 | 47.8 % of 23 cases reached ESRD | ND |
| Wehrmann [13] | 170 | 5.0:1 | ND | ND | ND | ND | ND | 5- and 10-year renal survival rates were 35.9 % and 23.6 %, respectively | Baseline Scr |
| Vikse [10] | 102 | 2.0:1 | 55.4 | 1.87(ND) | 0.4 | 156 ± 28(SBP); 92 ± 14(DBP) |
11.7 | 5- and 10-year renal survival rates were 80 % and 72 %, respectively | Baseline Scr, proteinuria |
| Norris [11] | 1094a | 1.6:1 | 54.6 | ND(46.4) | 0.3 | 150 ± 24(SBP); 96 ± 14(DBP) |
3.9 | 13.1 % reached endpoint event (50 % or 25 ml/min per 1.73 m2decline in GFR or ESRD) | Baseline proteinuria, GFR, Scr,urea nitrogen, phosphorus |
| Dasgupta [12] | 60 | 2.0:1 | 58.0 | 2.79(36.0) | 2.3 | 179 ± 25(SBP); 105 ± 15(DBP) |
6.7 | 5- and 10-year renal survival rates were 56 % and 35 %, respectively | Baseline Scr, mean SBP and DBP during follow-up (univariate analysis), DBP during follow-up (multivariate analysis) |
| Yu [39] | 61 | 9.2:1 | 32.0 | 6.33(ND) | 3.46 | ND | 2.5 | 45.9 % reached ESRD | ND |
| This study | 194 | 4.7:1 | 43.8 | 1.61(49.6) | 0.80 | 195 ± 37(SBP); 126 ± 26(DBP) |
3.0 | 5- and 10-year renal survival rates were 84.5 and 48.9 %, respectively | Baseline eGFR, proteinuria, anemia, the percentage of global glomerulosclerosis and TAIF |
aMost cases underwent renal biopsies
ND, no data; BP, blood pressure; MAP, mean blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MN, malignant nephrosclerosis; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; TAIF, tubular atrophy/interstitial fibrosis